We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-0.87%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$369B
AUM Growth
-$12.6B
(-3.3%)
Cap. Flow
+$3.24B
Cap. Flow
% of AUM
0.88%
Top 10 Holdings %
Top 10 Hldgs %
31.8%
Holding
3,300
New
48
Increased
1,756
Reduced
1,134
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$1.25B |
| 2 |
NXUS
Nuveen International Aggregate Bond ETF
NXUS
|
+$938M |
| 3 |
Apple
AAPL
|
+$911M |
| 4 |
Costco
COST
|
+$878M |
| 5 |
NVIDIA
NVDA
|
+$799M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.69B |
| 2 |
ServiceNow
NOW
|
+$651M |
| 3 |
Applied Materials
AMAT
|
+$563M |
| 4 |
Visa
V
|
+$536M |
| 5 |
Carnival Corporation Ltd
CCL
|
+$523M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.9% |
| 2 | Financials | 11.41% |
| 3 | Consumer Discretionary | 10.18% |
| 4 | Industrials | 9.65% |
| 5 | Healthcare | 9.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Blackbaud
BLKB
$1.5B
| $3.61M | ﹤0.01% |
93,558
-160,883
| -63% | -$8.03M |
|
2002
Axogen
AXGN
$2.1B
| $3.61M | ﹤0.01% |
108,941
-12,022
| -10% | -$391K |
|
2003
DoubleVerify
DV
$1.62B
| $3.6M | ﹤0.01% |
378,767
-158,628
| -30% | -$1.62M |
|
2004
Pebblebrook Hotel Trust 6.3% Series F Preferred Shares
PEB.PRF
$121M
| $3.58M | ﹤0.01% |
185,467
+130
| +0.1% | +$2.58K |
|
2005
LiveRamp
RAMP
$2.29B
| $3.58M | ﹤0.01% |
134,889
+1,009
| +0.8% | +$26.4K |
|
2006
Recursion Pharmaceuticals
RXRX
$1.57B
| $3.58M | ﹤0.01% |
1,164,603
+79,678
| +7% | +$308K |
|
2007
DXC Technology
DXC
$1.63B
| $3.57M | ﹤0.01% |
284,353
+4,496
| +2% | +$60.4K |
|
2008
i3 Verticals
IIIV
$395M
| $3.56M | ﹤0.01% |
159,050
-505
| -0.3% | -$11.8K |
|
|
EFXT
2009
Enerflex
EFXT
$2.78B
| $3.55M | ﹤0.01% |
170,398
+71,688
| +73% | +$1.37M |
|
|
ARI
2010
Apollo Commercial Real Estate
ARI
$887M
| $3.54M | ﹤0.01% |
334,905
-53,625
| -14% | -$558K |
|
2011
Stoke Therapeutics
STOK
$1.82B
| $3.54M | ﹤0.01% |
108,617
+4,356
| +4% | +$143K |
|
2012
Central Garden & Pet Co Class A
CENTA
$2.41B
| $3.53M | ﹤0.01% |
108,896
+2,957
| +3% | +$94.3K |
|
2013
Lucid Motors
LCID
$2.46B
| $3.52M | ﹤0.01% |
369,803
-8,340
| -2% | -$86.7K |
|
2014
Hippo Holdings
HIPO
$723M
| $3.52M | ﹤0.01% |
135,195
-5,332
| -4% | -$152K |
|
2015
Pilgrim's Pride
PPC
$6.82B
| $3.52M | ﹤0.01% |
93,121
+18,462
| +25% | +$745K |
|
2016
CorVel
CRVL
$3.05B
| $3.51M | ﹤0.01% |
64,183
-13,476
| -17% | -$776K |
|
|
SLNO
2017
DELISTED
Soleno Therapeutics
SLNO
| $3.51M | ﹤0.01% |
104,738
+4,116
| +4% | +$161K |
|
2018
Peoples Bancorp
PEBO
$1.45B
| $3.5M | ﹤0.01% |
106,515
-860
| -0.8% | -$27.7K |
|
2019
Ocular Therapeutix
OCUL
$1.86B
| $3.48M | ﹤0.01% |
411,080
-51,727
| -11% | -$493K |
|
2020
O-I Glass
OI
$1.39B
| $3.48M | ﹤0.01% |
331,151
-4,636
| -1% | -$63.8K |
|
|
SUNC
2021
SunocoCorp LLC
SUNC
$3.93B
| $3.48M | ﹤0.01% |
+56,398
| New | +$3.2M |
|
2022
Hope Bancorp
HOPE
$1.72B
| $3.48M | ﹤0.01% |
311,207
+41,022
| +15% | +$474K |
|
2023
EverQuote
EVER
$886M
| $3.45M | ﹤0.01% |
223,777
-374,829
| -63% | -$7.09M |
|
2024
Interparfums
IPAR
$3.92B
| $3.44M | ﹤0.01% |
37,882
-950
| -2% | -$90K |
|
2025
AdaptHealth
AHCO
$1.46B
| $3.42M | ﹤0.01% |
287,721
+8,268
| +3% | +$84.6K |
|
Similar funds
VFT
Nuveen's Q1 2026 Portfolio in Review
As of Q1 2026, Nuveen held 3,300 positions worth $369B, down 3.3% from $382B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Trading was light in Q1 2026: portfolio turnover was 3.8%. Nuveen opened 48 new positions and exited 76, leaving the 3,300-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 33% a quarter earlier, followed by Financials and Consumer Discretionary.
- Nuveen's largest Q1 2026 buy was Sunbelt Rentals Holdings: 2,483,995 shares worth $156M.
- Nuveen added most to AstraZeneca in Q1 2026, an estimated $1.25B increase.
- Nuveen's biggest Q1 2026 reduction was Microsoft, cutting an estimated $1.69B.
- Nuveen fully exited Exact Sciences in Q1 2026, selling an estimated $82.6M.
- Nuveen's ten largest holdings make up 32% of its $369B portfolio in Q1 2026.
- Nuveen opened 48 new positions and closed 76 in Q1 2026.
- Nuveen's portfolio value fell 3.3% quarter-over-quarter to $369B.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.